Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$50.0 million","newsHeadline":"Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$273.0 million","upfrontCash":"Undisclosed","newsHeadline":"Generate:Biomedicines Announces Close of $273M Series C Financing to Advance its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Generate Biomedicines

    Menu

    Generate Biomedicines

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Generate Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

              Details:

              The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.

              Lead Product(s): CAR T-Cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Generate Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Generate:Biomedicines Announces Close of $273M Series C Financing to Advance its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics

              Details:

              The financing will be used to advance company's Generative AI pipeline of preclinical and clinical protein therapeutics, including GB-0669, a monoclonal antibody targeting a highly conserved region of the spike protein, in SARS-CoV-2.

              Lead Product(s): GB-0669

              Therapeutic Area: Infections and Infectious Diseases Product Name: GB-0669

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amgen Inc

              Deal Size: $273.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing September 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Generate Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI

              Details:

              The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s clinical research expertise.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Generate Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement

              Details:

              Generate Biomedicine's integrated in silico design and wet lab capabilities combined with Amgen to harness its machine-learning-enabled technology to discover and develop protein therapeutics for five clinical targets across a range of therapeutic areas and modalities.

              Lead Product(s): Engineered Protein-based Therapy

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amgen Inc

              Deal Size: $1,900.0 million Upfront Cash: $50.0 million

              Deal Type: Collaboration January 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY